Top

Published in:

Open Access 01-12-2021 | Insomnia | Research

Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study

Authors: Aline HAJJ, Roula HACHEM, Rita KHOURY, Souheil HALLIT, Bashar ElJEBBAWI, Fady NASR, Fadi EL KARAK, Georges CHAHINE, Joseph KATTAN, Lydia RABBAA KHABBAZ

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Despite the progress in assessment and treatment of breast cancer, being diagnosed with it or receiving chemotherapy treatment is still conceived as a traumatic experience. Women develop negative thoughts about life and death with detrimental effects on their daily physical functioning/activities, emotional state and overall quality of life. The aim of our study was to evaluate the level of anxiety and depression among breast cancer patients receiving chemotherapy and explore the correlation between these psychological disorders, clinical, sociodemographic and genetic factors.

Methods

A cross-sectional study was conducted among breast cancer patients undergoing intravenous chemotherapy at the oncology outpatient unit of Hôtel-Dieu de France hospital (November 2017–June 2019; Ethical approval number: CEHDF1016). All patients gave their written informed consent and completed several validated scales, including the Hospital Anxiety and Depression scale (HADS) for the assessment of anxiety and depression. Sleep quality, insomnia, cognitive function, fatigue and pain were also evaluated. Genotyping for certain gene polymorphisms (CLOCK, PER2, CRY2, OPRM1, ABCB1, COMT, DRD2) was performed using the Lightcycler® (Roche).

Results

A total of 112 women was included. The prevalence of depression was 43.4%, and 56.2% of the patients reported anxiety (based on the HADS classification). Multivariable analysis showed that higher cognitive scores and taking fosaprepitant were significantly associated with lower depression and anxiety scores. Moreover, being married compared to single was also associated with lower depression scores, whereas higher PSQI scores (worse sleep quality) and having the PER2 AA variant genotype compared to GG were significantly associated with higher depression scores. Finally, reporting a more severe insomnia and having the COMT Met/Met genotype were significantly associated with a higher anxiety score.

Conclusions

Our study demonstrated a strong relationship between depression scores and cognitive impairment, sleep quality, marital status, fosaprepitant intake, and PER2 polymorphism, while anxiety scores were correlated to cognitive impairment, insomnia severity, fosaprepitant intake, and COMT polymorphism. The association with PER polymorphism was not previously reported. Identification of genetic and clinical risk factors for anxiety and depression would help clinicians implement an individualized management therapy aiming at preventing and alleviating the burden of these symptoms in breast cancer patients, hence improving their overall quality of life.

Huang HM, Lai JH, Huang TW. Mediating effects of depression on anxiety and leisure constraints in patients with breast cancer. BMC Womens Health. 2019;19(1):141. https://doi.org/10.1186/s12905-019-0838-7.CrossRefPubMedPubMedCentral

Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7(3):300–22. https://doi.org/10.1007/s11764-013-0272-z.CrossRefPubMed

Civilotti C, Acquadro Maran D, Santagata F, Varetto A, Stanizzo MR. The use of the distress thermometer and the hospital anxiety and depression scale for screening of anxiety and depression in Italian women newly diagnosed with breast cancer. Support Care Cancer. 2020;28(10):4997–5004. https://doi.org/10.1007/s00520-020-05343-x.CrossRefPubMed

Berman MG, Askren MK, Jung M, Therrien B, Peltier S, Noll DC, et al. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol. 2014;33(3):222–31. https://doi.org/10.1037/a0033425.CrossRefPubMed

An Y, Fu G, Yuan G. Quality of life in patients with breast Cancer: the influence of family Caregiver's burden and the mediation of Patient's anxiety and depression. J Nerv Ment Dis. 2019;207(11):921–6. https://doi.org/10.1097/NMD.0000000000001040.CrossRefPubMed

Shim EJ, Lee JW, Cho J, Jung HK, Kim NH, Lee JE, et al. Association of depression and anxiety disorder with the risk of mortality in breast cancer: a National Health Insurance Service study in Korea. Breast Cancer Res Treat. 2020;179(2):491–8. https://doi.org/10.1007/s10549-019-05479-3.CrossRefPubMed

Mandelblatt JS, Zhai W, Ahn J, Small BJ, Ahles TA, Carroll JE, et al. Symptom burden among older breast cancer survivors: the thinking and living with Cancer (TLC) study. Cancer. 2020;126(6):1183–92. https://doi.org/10.1002/cncr.32663.CrossRefPubMed

Yang GS, Kumar S, Dorsey SG, Starkweather AR, Kelly DL, Lyon DE. Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors. Support Care Cancer. 2019;27(2):351–71. https://doi.org/10.1007/s00520-018-4508-3.CrossRefPubMed

Park EM, Gelber S, Rosenberg SM, Seah DSE, Schapira L, Come SE, et al. Anxiety and depression in Young women with metastatic breast Cancer: a cross-sectional study. Psychosomatics. 2018;59(3):251–8. https://doi.org/10.1016/j.psym.2018.01.007.CrossRefPubMedPubMedCentral

10.

Lan B, Jiang S, Li T, Sun X, Ma F. Depression, anxiety, and their associated factors among Chinese early breast cancer in women under 35 years of age: a cross sectional study. Curr Probl Cancer. 2020;100558(5):100558. https://doi.org/10.1016/j.currproblcancer.2020.100558.CrossRef

11.

Naik H, Leung B, Laskin J, McDonald M, Srikanthan A, Wu J, et al. Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults. Breast Cancer Res Treat. 2020;179(2):471–7. https://doi.org/10.1007/s10549-019-05468-6.CrossRefPubMed

12.

Tsaras K, Papathanasiou IV, Mitsi D, Veneti A, Kelesi M, Zyga S, et al. Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors. Asian Pac J Cancer Prev. 2018;19(6):1661–9. https://doi.org/10.22034/APJCP.2018.19.6.1661.CrossRefPubMedPubMedCentral

13.

Shim EJ, Jeong D, Moon HG, Noh DY, Jung SY, Lee E, et al. Profiles of depressive symptoms and the association with anxiety and quality of life in breast cancer survivors: a latent profile analysis. Qual Life Res. 2020;29(2):421–9. https://doi.org/10.1007/s11136-019-02330-6.CrossRefPubMed

14.

Casavilca-Zambrano S, Custodio N, Liendo-Picoaga R, Cancino-Maldonado K, Esenarro L, Montesinos R, et al. Depression in women with a diagnosis of breast cancer. Prevalence of symptoms of depression in Peruvian women with early breast cancer and related sociodemographic factors. Semin Oncol. 2020;47(5):293–301. https://doi.org/10.1053/j.seminoncol.2020.08.003.CrossRefPubMed

15.

Stanton AL, Wiley JF, Krull JL, Crespi CM, Hammen C, Allen JJ, et al. Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer. Breast Cancer Res Treat. 2015;154(1):105–15. https://doi.org/10.1007/s10549-015-3563-4.CrossRefPubMedPubMedCentral

16.

Garcia-Garcia T, Carmona-Bayonas A, Jimenez-Fonseca P, Jara C, Beato C, Castelo B, et al. Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment. BMC Cancer. 2019;19(1):1143. https://doi.org/10.1186/s12885-019-6358-x.CrossRefPubMedPubMedCentral

17.

Karayol R, Medrihan L, Warner-Schmidt JL, Fait BW, Rao MN, Holzner EB, et al. Serotonin receptor 4 in the hippocampus modulates mood and anxiety. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-020-00994-y.

18.

Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009;20(12):1125–8. https://doi.org/10.1097/WNR.0b013e32832eb708.CrossRefPubMed

19.

Kiyohara C, Yoshimasu K. Association between major depressive disorder and a functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: a meta-analysis. Psychiatr Genet. 2010;20(2):49–58. https://doi.org/10.1097/YPG.0b013e328335112b.CrossRefPubMed

20.

Kim JM, Stewart R, Kim SY, Kang HJ, Jang JE, Kim SW, et al. A one year longitudinal study of cytokine genes and depression in breast cancer. J Affect Disord. 2013;148(1):57–65. https://doi.org/10.1016/j.jad.2012.11.048.CrossRefPubMed

21.

Schuch JB, Genro JP, Bastos CR, Ghisleni G, Tovo-Rodrigues L. The role of CLOCK gene in psychiatric disorders: evidence from human and animal research. Am J Med Genet B Neuropsychiatr Genet. 2018;177(2):181–98. https://doi.org/10.1002/ajmg.b.32599.CrossRefPubMed

22.

Liberman AR, Halitjaha L, Ay A, Ingram KK. Modeling strengthens molecular link between circadian polymorphisms and major mood disorders. J Biol Rhythm. 2018;33(3):318–36. https://doi.org/10.1177/0748730418764540.CrossRef

23.

Admon R, Kaiser RH, Dillon DG, Beltzer M, Goer F, Olson DP, et al. Dopaminergic enhancement of striatal response to reward in major depression. Am J Psychiatry. 2017;174(4):378–86. https://doi.org/10.1176/appi.ajp.2016.16010111.CrossRefPubMed

24.

Pecina M, Sikora M, Avery ET, Heffernan J, Pecina S, Mickey BJ, et al. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: implications for anhedonia, anxiety and treatment response. Eur Neuropsychopharmacol. 2017;27(10):977–86. https://doi.org/10.1016/j.euroneuro.2017.08.427.CrossRefPubMedPubMedCentral

25.

Kovanen L, Kaunisto M, Donner K, Saarikoski ST, Partonen T. CRY2 genetic variants associate with dysthymia. PLoS One. 2013;8(8):e71450. https://doi.org/10.1371/journal.pone.0071450.CrossRefPubMedPubMedCentral

26.

Kleinjan M, Rozing M, Engels RC, Verhagen M. Co-development of early adolescent alcohol use and depressive feelings: the role of the mu-opioid receptor A118G polymorphism. Dev Psychopathol. 2015;27(3):915–25. https://doi.org/10.1017/S0954579414000911.CrossRefPubMed

27.

Swann G, Byck GR, Dick DM, Aliev F, Latendresse SJ, Riley B, et al. Effect of OPRM1 and stressful life events on symptoms of major depression in African American adolescents. J Affect Disord. 2014;162:12–9. https://doi.org/10.1016/j.jad.2014.03.020.CrossRefPubMedPubMedCentral

28.

Slavich GM, Tartter MA, Brennan PA, Hammen C. Endogenous opioid system influences depressive reactions to socially painful targeted rejection life events. Psychoneuroendocrinology. 2014;49:141–9. https://doi.org/10.1016/j.psyneuen.2014.07.009.CrossRefPubMedPubMedCentral

29.

Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63(11):1199–208. https://doi.org/10.1001/archpsyc.63.11.1199.CrossRefPubMed

30.

Ozbey G, Yucel B, Taycan SE, Kan D, Bodur NE, Arslan T, et al. ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population. Pharmacol Rep. 2014;66(2):235–8. https://doi.org/10.1016/j.pharep.2013.09.004.CrossRefPubMed

31.

Fujii T, Ota M, Hori H, Sasayama D, Hattori K, Teraishi T, et al. Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. J Psychiatr Res. 2012;46(4):555–9. https://doi.org/10.1016/j.jpsychires.2012.01.012.CrossRefPubMed

32.

Hoth KF, Paul RH, Williams LM, Dobson-Stone C, Todd E, Schofield PR, et al. Associations between the COMT Val/met polymorphism, early life stress, and personality among healthy adults. Neuropsychiatr Dis Treat. 2006;2(2):219–25. https://doi.org/10.2147/nedt.2006.2.2.219.CrossRefPubMedPubMedCentral

33.

Joe KH, Kim DJ, Park BL, Yoon S, Lee HK, Kim TS, et al. Genetic association of DRD2 polymorphisms with anxiety scores among alcohol-dependent patients. Biochem Biophys Res Commun. 2008;371(4):591–5. https://doi.org/10.1016/j.bbrc.2008.02.076.CrossRefPubMed

34.

Noh T, Walbert T. Brain metastasis: clinical manifestations, symptom management, and palliative care. Handb Clin Neurol. 2018;149:75–88. https://doi.org/10.1016/B978-0-12-811161-1.00006-2.CrossRefPubMed

35.

Lee PE, Tierney MC, Wu W, Pritchard KI, Rochon PA. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. Breast Cancer Res Treat. 2016;158(3):407–20. https://doi.org/10.1007/s10549-016-3906-9.CrossRefPubMed

36.

Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, et al. Patient-reported cognitive impairment among women with early breast Cancer randomly assigned to endocrine therapy alone versus Chemoendocrine therapy: results from TAILORx. J Clin Oncol. 2020;38(17):1875–86. https://doi.org/10.1200/JCO.19.01866.CrossRefPubMedPubMedCentral

37.

Medscape. BMI and BSA (Mosteller). 2020. Retrieved July 26 from https://reference.medscape.com/calculator/28/bmi-and-bsa-mosteller.

38.

Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55(4):515–24. https://doi.org/10.1016/j.metabol.2005.11.004.

39.

Hajj A, Hachem R, Khoury R, Nehme T, Hallit S, Nasr F, et al. Clinical and Genetic factors associated with the Breast cancer-related Sleep Disorders: The “CAGE-Sleep” study- a cross-sectional study. J Pain Symptom Manag. 2021; In Press.

40.

Hartung TJ, Friedrich M, Johansen C, Wittchen HU, Faller H, Koch U, et al. The hospital anxiety and depression scale (HADS) and the 9-item patient health questionnaire (PHQ-9) as screening instruments for depression in patients with cancer. Cancer. 2017;123(21):4236–43. https://doi.org/10.1002/cncr.30846.CrossRefPubMed

41.

Lange M, Heutte N, Morel N, Eustache F, Joly F, Giffard B. Cognitive complaints in cancer: the French version of the functional assessment of Cancer therapy-cognitive function (FACT-cog), normative data from a healthy population. Neuropsychol Rehabil. 2016;26(3):392–409. https://doi.org/10.1080/09602011.2015.1036890.CrossRefPubMed

42.

Akman T, Yavuzsen T, Sevgen Z, Ellidokuz H, Yilmaz AU. Evaluation of sleep disorders in cancer patients based on Pittsburgh sleep quality index. Eur J Cancer Care (Engl). 2015;24(4):553–9. https://doi.org/10.1111/ecc.12296.CrossRef

43.

Gehrman PR, Garland SN, Matura LA, Mao J. Insomnia in breast cancer: independent symptom or symptom cluster? Palliat Support Care. 2017;15(3):369–75. https://doi.org/10.1017/S1478951516000900.CrossRefPubMed

44.

Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, et al. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer. 2020;125:69–82. https://doi.org/10.1016/j.ejca.2019.10.031.CrossRefPubMed

45.

Ovayolu O, Ovayolu N, Aytac S, Serce S, Sevinc A. Pain in cancer patients: pain assessment by patients and family caregivers and problems experienced by caregivers. Support Care Cancer. 2015;23(7):1857–64. https://doi.org/10.1007/s00520-014-2540-5.CrossRefPubMed

46.

Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019;22(1):67–72. https://doi.org/10.4103/aca.ACA_157_18.CrossRefPubMedPubMedCentral

47.

Ghasemi A, Zahediasl S. Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab. 2012;10(2):486–9. https://doi.org/10.5812/ijem.3505.CrossRefPubMedPubMedCentral

48.

Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25(12):3186–97. https://doi.org/10.1038/s41380-020-00865-6.CrossRefPubMedPubMedCentral

49.

Akel R, El Darsa H, Anouti B, Mukherji D, Temraz S, Raslan R, et al. Anxiety, Depression and Quality of Life in Breast Cancer Patients in the Levant. Asian Pac J Cancer Prev. 2017;18(10):2809–16. https://doi.org/10.22034/APJCP.2017.18.10.2809.CrossRefPubMedPubMedCentral

50.

Shin JA, El-Jawahri A, Parkes A, Schleicher SM, Knight HP, Temel JS. Quality of life, mood, and prognostic understanding in patients with metastatic breast Cancer. J Palliat Med. 2016;19(8):863–9. https://doi.org/10.1089/jpm.2016.0027.CrossRefPubMedPubMedCentral

51.

Song HM, Cho CH, Lee HJ, Moon JH, Kang SG, Yoon HK, et al. Association of CLOCK, ARNTL, PER2, and GNB3 polymorphisms with diurnal preference in a Korean population. Chronobiol Int. 2016;33(10):1455–63. https://doi.org/10.1080/07420528.2016.1231199.CrossRefPubMed

52.

Lesicka M, Jablonska E, Wieczorek E, Peplonska B, Gromadzinska J, Seroczynska B, et al. Circadian Gene Polymorphisms Associated with Breast Cancer Susceptibility. Int J Mol Sci. 2019;20(22):5704. https://doi.org/10.3390/ijms20225704.

53.

Albrecht U. Molecular connections between circadian clocks and mood-related behaviors. J Mol Biol. 2020;432(12):3714–21. https://doi.org/10.1016/j.jmb.2019.11.021.CrossRefPubMed

54.

Schnell A, Albrecht U, Sandrelli F. Rhythm and mood: relationships between the circadian clock and mood-related behavior. Behav Neurosci. 2014;128(3):326–43. https://doi.org/10.1037/a0035883.CrossRefPubMed

55.

Young EE, Kelly DL, Shim I, Baumbauer KM, Starkweather A, Lyon DE. Variations in COMT and NTRK2 influence symptom burden in women undergoing breast Cancer treatment. Biol Res Nurs. 2017;19(3):318–28. https://doi.org/10.1177/1099800417692877.CrossRefPubMedPubMedCentral

56.

Qin X, Peng Q, Qin A, Chen Z, Lin L, Deng Y, et al. Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. Diagn Pathol. 2012;7(1):136. https://doi.org/10.1186/1746-1596-7-136.CrossRefPubMedPubMedCentral

57.

Ren X, Zhang L, Xiao Q, Huang D, Liu Q, Zhang Y. Association between COMT polymorphism, labor anxiety, and analgesia in pregnant women. J Pain Res. 2019;12:779–85. https://doi.org/10.2147/JPR.S192719.CrossRefPubMedPubMedCentral

58.

Jorm AF, Prior M, Sanson A, Smart D, Zhang Y, Tan S, et al. Lack of association of a single-nucleotide polymorphism of the mu-opioid receptor gene with anxiety-related traits: results from a cross-sectional study of adults and a longitudinal study of children. Am J Med Genet. 2002;114(6):659–64. https://doi.org/10.1002/ajmg.10643.CrossRefPubMed

59.

Kim KM, Choi SW, Kim D, Lee J, Kim JW. Associations among the opioid receptor gene (OPRM1) A118G polymorphism, psychiatric symptoms, and quantitative EEG in Korean males with gambling disorder: a pilot study. J Behav Addict. 2019;8(3):463–70. https://doi.org/10.1556/2006.8.2019.41.CrossRefPubMedPubMedCentral

60.

Kishi T, Yoshimura R, Fukuo Y, Kitajima T, Okochi T, Matsunaga S, et al. The CLOCK gene and mood disorders: a case-control study and meta-analysis. Chronobiol Int. 2011;28(9):825–33. https://doi.org/10.3109/07420528.2011.611602 10.3109/07420528.2011.609951.CrossRefPubMed

61.

Calati R, Gaspar-Barba E, Yukler A, Serretti A. T3111C clock single nucleotide polymorphism and mood disorders: a meta-analysis. Chronobiol Int. 2010;27(4):706–21. https://doi.org/10.3109/07420521003681480.CrossRefPubMed

62.

Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008;8(11):1733–42. https://doi.org/10.1586/14737140.8.11.1733.CrossRefPubMed

63.

Garcia-Recio S, Gascon P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int. 2015;2015:495704–14. https://doi.org/10.1155/2015/495704.CrossRefPubMedPubMedCentral

64.

Langford P, Chrisp P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2010;5:77–90. https://doi.org/10.2147/ce.s6012.CrossRefPubMedPubMedCentral

65.

Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94(1):265–301. https://doi.org/10.1152/physrev.00031.2013.CrossRefPubMedPubMedCentral

66.

Thompson T, Perez M, Kreuter M, Margenthaler J, Colditz G, Jeffe DB. Perceived social support in African American breast cancer patients: predictors and effects. Soc Sci Med. 2017;192:134–42. https://doi.org/10.1016/j.socscimed.2017.09.035.CrossRefPubMedPubMedCentral

67.

Kim HJ, Barsevick AM, Tulman L, McDermott PA. Treatment-related symptom clusters in breast cancer: a secondary analysis. J Pain Symptom Manag. 2008;36(5):468–79. https://doi.org/10.1016/j.jpainsymman.2007.11.011.CrossRef

68.

Albusoul RM, Berger AM, Gay CL, Janson SL, Lee KA. Symptom clusters change over time in women receiving adjuvant chemotherapy for breast Cancer. J Pain Symptom Manag. 2017;53(5):880–6. https://doi.org/10.1016/j.jpainsymman.2016.12.332.CrossRef

69.

Berger AM, Kumar G, LeVan TD, Meza JL. Symptom clusters and quality of life over 1 year in breast Cancer patients receiving adjuvant chemotherapy. Asia Pac J Oncol Nurs. 2020;7(2):134–40. https://doi.org/10.4103/apjon.apjon_57_19.CrossRefPubMedPubMedCentral

70.

Chen PJ, Huang CL, Weng SF, Wu MP, Ho CH, Wang JJ, et al. Relapse insomnia increases greater risk of anxiety and depression: evidence from a population-based 4-year cohort study. Sleep Med. 2017;38:122–9. https://doi.org/10.1016/j.sleep.2017.07.016.CrossRefPubMed

71.

Mason EC, Harvey AG. Insomnia before and after treatment for anxiety and depression. J Affect Disord. 2014;168:415–21. https://doi.org/10.1016/j.jad.2014.07.020.CrossRefPubMed

72.

Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11(5):279–92. https://doi.org/10.1159/000079408.CrossRefPubMed

73.

Wood LJ, Nail LM, Gilster A, Winters KA, Elsea CR. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum. 2006;33(3):535–42. https://doi.org/10.1188/06.ONF.535-542.CrossRefPubMed

74.

Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–82. https://doi.org/10.1200/JCO.2007.10.7805.CrossRefPubMed

75.

Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A, et al. Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012;136(3):789–94. https://doi.org/10.1007/s10549-012-2311-2.CrossRefPubMed

76.

Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236–8. https://doi.org/10.1136/bmj.316.7139.1236.CrossRefPubMedPubMedCentral

77.

Veazie PJ. When to combine hypotheses and adjust for multiple tests. Health Serv Res. 2006;41(3 Pt 1):804–18. https://doi.org/10.1111/j.1475-6773.2006.00512.x.CrossRefPubMedPubMedCentral

78.

Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):17. https://doi.org/10.1186/1751-0473-3-17.CrossRefPubMedPubMedCentral

79.

Dahiru T. P - value, a true test of statistical significance? A cautionary note. Ann Ib Postgrad Med. 2008;6(1):21–6. https://doi.org/10.4314/aipm.v6i1.64038.CrossRefPubMedPubMedCentral

Title: Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study
Authors: Aline HAJJ
Roula HACHEM
Rita KHOURY
Souheil HALLIT
Bashar ElJEBBAWI
Fady NASR
Fadi EL KARAK
Georges CHAHINE
Joseph KATTAN
Lydia RABBAA KHABBAZ
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Insomnia
Mood Disorders
Breast Cancer
Affective Disorder
Breast Cancer
Anxiety
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08615-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Super-enhancer-associated long noncoding RNA AC005592.2 promotes tumor progression by regulating OLFM4 in colorectal cancer

Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancer

Humanized anti-DEspR IgG4S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis ratnu/nu model

Mixed methods assessment of impact on health awareness in adult childhood cancer survivors after viewing their personalized digital treatment summary and follow-up recommendations

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions

The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Keynote webinar | Spotlight on antibody–drug conjugates in cancer